Biostability, durability and calcification of cryopreserved human pericardium after rapid glutaraldehyde-stabilization versus multistep ADAPT(R) treatment in a subcutaneous rat model
| Autor: | William M L Neethling, Christian P. Brizard, Laura Firth, Ross Glancy |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine medicine.medical_specialty Urology chemistry.chemical_element Absorption (skin) Calcium Cryopreservation Intracardiac injection chemistry.chemical_compound Materials Testing Animals Humans Medicine Pericardium Rats Wistar Analysis of Variance Microscopy business.industry Calcinosis Histology General Medicine medicine.disease Rats Surgery medicine.anatomical_structure chemistry Glutaral Cattle Glutaraldehyde Cardiology and Cardiovascular Medicine business Calcification |
| Zdroj: | European Journal of Cardio-Thoracic Surgery. 45:e110-e117 |
| ISSN: | 1873-734X 1010-7940 |
| DOI: | 10.1093/ejcts/ezt623 |
| Popis: | OBJECTIVES: Autologous pericardium rapidly fixed with glutaraldehyde (GA) in theatre is considered in many cardiac surgery centres the best material currently available for intracardiac, valvular or vascular repair. Implanted non-fixed autologous tissues suffer rapid degeneration, shrinkage and absorption whereas standard xenotypic fixed tissues cause local cytotoxicity and calcification. In the present study, using a subcutaneous rat model, we tested the biostability, durability and calcification potential of four different pericardium patches treated with GA and relevant to current clinical practice. METHODS: Pericardium samples were divided into four groups according to the method of treatment. Group I consisted of bovine pericardium (BP) fixed with 0.6% GA (control), Group II cryopreserved human pericardium (CHP) rapidly fixed with 0.6% GA for 4 min and detoxified with MgCl2, Group III CHP treated with the multistep ADAPT ® process (delipidized, decellularized with Tx-100, deoxycholate, IgePal CA-630 and denucleased, fixed in 0.05% monomeric GA and detoxified) and Group IV BP treated with the multistep ADAPT ® process (CardioCel ® ). Biostability was determined by shrinkage temperature which measures the degree of cross-linking, and durability assessed by resistance to a mixture of proteinases (pronase digestion). Treated pericardium samples (n= 10 in each of Groups I–IV) were implanted in the subcutaneous rat model for 8 and 16 weeks, followed by histology and calcium analysis (atomic absorption spectrophotometry). RESULTS: The biostability and the durability of both CHP and BP after the multistep ADAPT ® treatment remained stable without any microscopic calcification. Extractable calcium levels of CHP were significantly (P< 0.01) reduced in Group II (1.89 ± 0.77 μg Ca/mg tissue) compared with Group I (64.37 ± 6.25 μg/mg) after 8 weeks. Calcification of CHP (Group III) and BP (Group IV) after the multistep ADAPT ® treatment was significantly reduced (1.43±0.48 µg/mg and 0.75±0.10 μg/mg, respectively) compared with Group I (282.52±18.26 μg/mg) and the rapidly treated CHP in Group II (11.32±3.21 μg/mg) after 16 weeks. CONCLUSIONS: Improved biostability and durability with reduced calcification of tissues after the multistep ADAPT ® tissue treatment suggest improved alternative substitutes to autologous pericardium. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|